ev3 CE marks carotid stent, US trial underway
This article was originally published in Clinica
Endovascular medical device firm ev3 is pressing ahead with efforts to exploit the carotid artery stent market. It recently gained the all-clear to sell its Protege GPS nitinol self-expanding tapered stent for treating carotid artery disease in Europe, and expects to complete a major US trial of its carotid products in the third quarter of this year.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.